Anika Therapeutics Inc
NASDAQ:ANIK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
US |
|
G
|
Golden MV Holdings Inc
XPHS:HVN
|
PH |
|
Dynex Capital Inc
NYSE:DX
|
US |
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
TC Energy Corp
TSX:TRP
|
CA |
|
Caltagirone SpA
MIL:CALT
|
IT |
|
S
|
SA Corporate Real Estate Fund Managers (Pty) Ltd
JSE:SAC
|
ZA |
|
N
|
Nikkon Holdings Co Ltd
OTC:NIPKF
|
JP |
|
C
|
Crown Holdings Inc
XBER:CWN
|
US |
|
E
|
Emira Property Fund
JSE:EMI
|
ZA |
|
T
|
Takeda Pharmaceutical Co Ltd
XBER:TKD
|
JP |
|
T
|
Target Corp
DUS:DYH
|
US |
|
CubeSmart
NYSE:CUBE
|
US |
|
Midea Real Estate Holding Ltd
F:MR9
|
CN |
|
S
|
Sappi Ltd
JSE:SAP
|
ZA |
|
A
|
Assetwise PCL
SET:ASW
|
TH |
|
D
|
Dollar Tree Inc
XBER:DT3
|
US |
|
MillerKnoll Inc
F:MHR
|
US |
|
BlackRock New York Municipal Income Trust
NYSE:BNY
|
US |
|
C
|
Coherent Corp
F:H7B
|
US |
|
P
|
Prysmian SpA
XMUN:AEU
|
IT |
|
K
|
Koninklijke Philips NV
MIL:PHIA
|
NL |
|
C
|
Central Japan Railway Co
SWB:JAP
|
JP |
|
N
|
NiSource Inc
SWB:NOU
|
US |
Wall St Price Targets
ANIK Price Targets Summary
Anika Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ANIK is 17.85 USD with a low forecast of 17.17 USD and a high forecast of 18.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ANIK's stock price target?
Price Target
17.85
USD
According to Wall Street analysts, the average 1-year price target for
ANIK is 17.85 USD with a low forecast of 17.17 USD and a high forecast of 18.9 USD.
What is the Revenue forecast for Anika Therapeutics Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 7%.
What is the Gross Profit forecast for Anika Therapeutics Inc?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 2 years is 6%.